Freenome
Biotech company specializing in early cancer diagnoses
Actively Hiring
Top Tier Investor
Overview
Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent diseases. If you crave challenges, understudied problems, and the chance to see your work impact the millions of lives touched by cancer, there’s no better place to be.
We are committed to our core values of empathy, integrity, and trust enable us to push through challenges, learn from mistakes, and support one another to reach our fullest potential.
By applying advanced ML techniques to recent breakthroughs in genomic science, Freenome is developing simple blood tests to detect early-stage cancer and make treatments more effective. The company has raised $238M from investors such as RA Capital, Polaris Partners, Perceptive Advisors, a16z, funds/accounts advised by T. Rowe Price Associates, Inc., GV (fka Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society’s BrightEdge Ventures, Data Collective Venture Capital, & Verily Life Sciences.
We are committed to our core values of empathy, integrity, and trust enable us to push through challenges, learn from mistakes, and support one another to reach our fullest potential.
By applying advanced ML techniques to recent breakthroughs in genomic science, Freenome is developing simple blood tests to detect early-stage cancer and make treatments more effective. The company has raised $238M from investors such as RA Capital, Polaris Partners, Perceptive Advisors, a16z, funds/accounts advised by T. Rowe Price Associates, Inc., GV (fka Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society’s BrightEdge Ventures, Data Collective Venture Capital, & Verily Life Sciences.
Industries
Biotechnology
Healthcare
Diagnostics
Personal Health
Technology